Insulet Corporation
Insulet Announces CFO Transition and Exceeds Revenue Guidance
Summary
Insulet Corporation announced on September 16, 2025, the appointment of Flavia H. Pease as the new Executive Vice President and Chief Financial Officer, effective September 30, 2025. The current CFO, Ana M. Chadwick, will transition to a Senior Advisor role to ensure a smooth handover. Additionally, the company expects to exceed its previously issued third quarter 2025 total revenue growth guidance.
Profitelligence Alerts
Get alerts for PODD
Be first to know when Insulet Corporation files with the SEC.
Filing Categories
Advertisement
About Insulet Corporation
Insulet Corporation is a prominent healthcare company specializing in medical devices, with a key focus on diabetes management. Its flagship product, the Omnipod Insulin Management System, is an innovative, tubeless insulin pump that offers users freedom and flexibility, addressing the lifelong needs of individuals with diabetes. The system is acclaimed for its discreet, water-resistant pods, which deliver continuous insulin delivery without the constraints of traditional insulin pumps. Insulet Corporation plays a crucial role in the medical technology industry by enhancing patient experiences and outcomes. Headquartered in Acton, Massachusetts, Insulet Corporation continues to pioneer advancements in insulin delivery solutions, directly impacting healthcare providers and improving the quality of life for diabetes patients globally. Its market significance is underscored by its commitment to innovation and accessibility, bridging the gap between technology and patient-centric care in the rapidly evolving healthcare sector.
Official SEC Documents
Advertisement